Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Classical hematology 2Breast 2Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 369Carcinoma, Non-Small-Cell Lung 315Neoplasms 289Prostatic Neoplasms 245Colorectal Neoplasms 214Multiple Myeloma 182Lung Neoplasms 170Neoplasm Metastasis 152Leukemia, Myeloid, Acute 137Pancreatic Neoplasms 130Squamous Cell Carcinoma of Head and Neck 127Ovarian Neoplasms 117Melanoma 98Carcinoma, Renal Cell 94Recurrence 87Stomach Neoplasms 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 80Carcinoma, Hepatocellular 80Lymphoma, Non-Hodgkin 79Head and Neck Neoplasms 79Lymphoma 78Glioblastoma 78Triple Negative Breast Neoplasms 76Lymphoma, Large B-Cell, Diffuse 75Urinary Bladder Neoplasms 69Endometrial Neoplasms 68Brain Neoplasms 68Leukemia, Lymphocytic, Chronic, B-Cell 65Uterine Cervical Neoplasms 62Lymphoma, Follicular 62

Interventions

durvalumab 2Tretinoin 2Paclitaxel 2Carboplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1talazoparib 1sarilumab 1pexidartinib 1pertuzumab 1pembrolizumab 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1dostarlimab 1cemiplimab 1abemaciclib 1Trastuzumab 1Standard of Care 1STA 9090 1SGN-LIV1A 1Pemetrexed 1MK 2206 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × 30 days × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07586813 2026-05-14

N01-A-PICIT-GI

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
Classical hematologyGastrointestinal

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡